SAT0483 SAFETY OF INTRAVENOUS IBANDRONIC ACID IN CHRONIC KIDNEY DISEASE: A REAL WORLD EXPERIENCE. (13th June 2020)

• Record Type: Journal Article
• Authors: Southern, J.; Chakravorty, M.; Lee, L. H.
• Is Part Of: Annals of the rheumatic diseases. Volume 79(2020)Supplement 1
• Page Start: 1198
• Page End: 1198
• Publication Date: 2020-06-13
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2020-eular.840
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Common forms of intravenous bisphosphonate used at the Royal Derby Hospital are zoledronic acid and ibandronic acid for a variety of indications. In the treatment of osteoporosis, zoledronic acid is preferred due to its convenience of once-yearly dosing; compared to ibandronic acid which is given three-monthly. Zoledronic acid is contraindicated in patients with an estimated glomerular filtration rate (eGFR) of less than 35 due to nephrotoxicity concerns. Ibandronic acid, however, is generally offered with an eGFR of 30 or over and is perceived to be a safer choice in more advanced chronic kidney disease. The potential of extending the use of ibandronic acid to patients with lower eGFR is being explored. However, there is a paucity of real world data and this study will therefore seek to affirm the safety profile in those on treatment. Objectives: Establish the safety profile of IV ibandronic acid with regards to worsening renal function or significant hypocalcaemia injury in the context of reduced renal clearance. Methods: The details of patients receiving IV ibandronic acid at Royal Derby Hospital were retrieved from the osteoporosis department register in September 2019. Data was collected anonymously from records using the electronic prescribing and pathology hospital database, together with electronic letters. The first three pre-infusion serum adjusted calcium levels, vitamin D, creatinine and eGFR were recorded. In addition, results from initiation to present were screened for any episodes of hypocalcaemia, acute kidney injury (AKI) or significant decline in renal function. Results: Treatment duration ranged from 6 months to 6 years. Female:male ratio was 9:1 and the average age was 75 years (range 50-90). Baseline eGFR ranged from 27 to over 60; 3 patients had eGFR≥60, 2 had eGFR 27 while remaining patients (75%) had eGFR 30-59. All patients received a standard 3mg infusion on each occasion. The most common rationale cited for ibandronic acid choice as opposed to zoledonic acid was reduced creatinine clearance or eGFR. Three patients (15%) developed one or more episodes of mild hypocalcaemia (lowest 2.01 mmol/l). No episodes of hypocalcaemia were identified in the first three pre-infusion levels. Four patients (25%) had a decline in eGFR by more than 5 ml/min/1.73m 2 but there was no definitive causal link with ibandronic acid and was most commonly felt to be related to their underlying renal disease. Three patients (15%) had at least one episode of AKI since commencing treatment, each explained by an intercurrent illness. Serum Vitamin D levels were measured pre-infusion in 92% of cases. Conclusion: This study reaffirms the safety profile of ibandronic acid use in renal function as low as CKD Stage 3b (≥30ml/min/1.73m 2 ). No episodes of AKI or sustained decline in renal function were causally linked to ibandronic acid. References: Royal Derby Hospital Proposed Clinical Guideline (2019) – Use of ibandronic acid in CKD 4 at reduced dosage. Disclosure of Interests: None declared